Globus Medical Inc. (GMED)
GMED Stock Might Rise From the Commercial Launch of Its ExcelsiusHub
Globus Medical commercially launches ExcelsiusHub navigation system to elevate the standard for freehand navigation.
Globus Medical, Inc. (GMED) Hit a 52 Week High, Can the Run Continue?
Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Globus Medical (GMED) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Globus Medical (GMED) a Solid Growth Stock? 3 Reasons to Think "Yes"
Globus Medical (GMED) possesses solid growth attributes, which could help it handily outperform the market.
GMED or SONVY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two companies is the best option for those looking for undervalued stocks?
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GMED Q3 Earnings Top, '24 Guidance Raised, Stock Gains in Aftermarket
Globus Medical delivers massive sales and earnings growth in the third quarter of 2024. However, margins contract.
Globus Medical, Inc. (GMED) Q3 2024 Earnings Call Transcript
Globus Medical, Inc. (NYSE:GMED ) Q3 2024 Earnings Conference Call November 5, 2024 6:00 PM ET Company Participants Brian Kearns - SVP, Business Development and IR Daniel Scavilla - President and CEO Keith Pfeil - COO and CFO Conference Call Participants Matthew Miksic - Barclays Dino Weinstock - Wells Fargo Young Li - Jefferies Shagun Singh - RBC Capital Markets Phil Dantoin - Piper Sandler David Saxon - Needham & Company Steven Lichtman - Oppenheimer Matthew Blackman - Stifel Ryan Zimmerman - BTIG Craig Bijou - BofA Caitlin Cronin - Canaccord Richard Newitter - Truist Securities Operator Welcome to Globus Medical's Third Quarter 2024 Earnings Call. At this time, all lines will be on mute and a Q&A session will be held after the prepared remarks.
Globus Medical (GMED) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Beats Q3 Earnings and Revenue Estimates
Globus Medical (GMED) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.57 per share a year ago.
Globus Medical, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or "the Company") (NYSE:GMED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
